Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
19.4 ILa | +7.18% | -16.02% | -39.18% |
Mar. 14 | Purple Biotech Reports Preclinical Proof of Concept for Its Tribody Platform Technology | CI |
Mar. 05 | Purple Biotech Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 13.69M 5.15B |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 20 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.59% |
1 day | +7.18% | ||
1 week | -16.02% | ||
Current month | -21.46% | ||
1 month | -24.51% | ||
3 months | -22.40% | ||
6 months | -69.88% | ||
Current year | -39.18% |
Managers | Title | Age | Since |
---|---|---|---|
Gil Efron
CEO | Chief Executive Officer | 57 | 18-10-10 |
Lior Fhima
DFI | Director of Finance/CFO | - | 22-11-01 |
Ido Morpurgo
COO | Chief Operating Officer | 51 | 20-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric Rowinsky
CHM | Chairman | 67 | 19-10-01 |
Yael Margolin
BRD | Director/Board Member | 70 | Dec. 19 |
Simcha Rock
BRD | Director/Board Member | 73 | 13-07-10 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-21 | 19.4 | +7.18% | 344,127 |
24-04-18 | 18.1 | -3.72% | 279,020 |
24-04-17 | 18.8 | -15.70% | 1,399,223 |
24-04-16 | 22.3 | -3.46% | 291,453 |
24-04-15 | 23.1 | -1.70% | 398,553 |
Delayed Quote TEL AVIV STOCK EXCHANGE, April 21, 2024 at 08:49 am EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-39.18% | 13.64M | |
+2.49% | 96.73B | |
-0.38% | 21.31B | |
-16.61% | 21.21B | |
-5.61% | 18.79B | |
-42.14% | 16.37B | |
-27.40% | 13.68B | |
+1.44% | 13.44B | |
+21.29% | 10.98B | |
-21.79% | 8.56B |
- Stock Market
- Equities
- PPBT Stock